KZIA on Nasdaq

KAZIA THERAPEUTICS LTD

Pharmaceutical preparations company based in Sydney Nsw. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

42.0KRevenue, fiscal 2025²

-20.7MNet income, fiscal 2025²

Compare with ALTERITY THERAPEUTICS LTD or Immutep, or pick any stock.

TickerKZIA on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersC3¹
Incorporated inAustralia³
Business addressThree International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 2000³
Filer categoryNon-accelerated filer³
Legal formCorporation

See how the biggest companies compare on our leaderboards

Kazia Therapeutics Limited (“Kazia” or the “Company”), a public company limited by shares, was incorporated in March 1994 and registered in New South Wales, Australia. Kazia is registered and operates under the Corporations Act.⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in AUD, the currency the company reports in.

Key numbers, fiscal 2025

-49290.5%Net margin²

-98.2%Revenue growth, 2025²

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentSelling, general and admin

Research and development41¢7.3M AUD
Selling, general and admin49¢8.7M AUD
Income tax10¢1.7M AUD

Out of 42.0K AUD in revenue.² The company lost money this year.

Financial statements

Revenue⁵²42.0K AUD in 2025−65% since 2018

Net income⁶⁷⁸⁹¹⁰²-20.7M AUD in 2025+243% since 2018

Every line of the income statement as filed: the last 3 fiscal years, latest first.²

Period ending	2025-06-30	2024-06-30	2023-06-30
Revenue	42.0K AUD	2.3M AUD	0 AUD
Other income	1.8M AUD	173.0K AUD	1.0K AUD
Finance income	72.0K AUD	12.0K AUD	22.0K AUD
Research and development expense	-7.3M AUD	-17.4M AUD	-15.6M AUD
General and administrative expense	-8.7M AUD	-13.6M AUD	-8.6M AUD
Impairment of intangible assets	-13.4M AUD	0 AUD	0 AUD
(Loss) gain on remeasurement of other financial liabilities	-2.5M AUD	1.3M AUD	0 AUD
Gain on remeasurement of promissory note	0 AUD	25.0K AUD	0 AUD
Gain on remeasurement of contingent consideration	7.6M AUD	119.0K AUD	3.4M AUD
Loss before income tax benefit	-22.4M AUD	-27.0M AUD	-20.7M AUD
Income tax benefit	1.7M AUD	271.0K AUD	271.0K AUD
Loss after income tax benefit	-20.7M AUD	-26.8M AUD	-20.5M AUD
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax	-23.0K AUD	-8.0K AUD	110.0K AUD
Other comprehensive income (loss), net of tax	-23.0K AUD	-8.0K AUD	110.0K AUD
Total comprehensive income/(loss)	-20.7M AUD	-26.8M AUD	-20.4M AUD
Basic earnings per share	-0.04 AUD	-0.10 AUD	-0.11 AUD
Diluted earnings per share	-0.04 AUD	-0.10 AUD	-0.11 AUD

Total assets⁵⁶⁷⁹¹⁰²6.1M AUD in 2025−78% since 2018

Total liabilities⁵⁶⁷⁹¹⁰²14.4M AUD in 2025+61% since 2018

Shareholders’ equity⁷⁸⁹12.1M AUD in 2023−37% since 2018

Cash⁷⁸⁹²4.3M AUD in 2025−27% since 2018

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.²

Period ending	2025-06-30	2024-12-31	2024-06-30	2023-06-30	2022-06-30
Cash and cash equivalents	4.3M AUD		1.7M AUD	5.2M AUD	7.4M AUD
Trade and other receivables	98.0K AUD		3.9M AUD
Other current assets	491.0K AUD		591.0K AUD
Total current assets	4.9M AUD		6.1M AUD
Other receivables	40.0K AUD		40.0K AUD
Intangibles	1.1M AUD	0 AUD	15.4M AUD	17.3M AUD
Total non-current assets	1.1M AUD		15.4M AUD
Total assets	6.1M AUD		21.6M AUD
Trade and other payables	10.1M AUD		15.1M AUD
Other financial liabilities	3.1M AUD		6.5M AUD	8.6M AUD
Borrowings	396.0K AUD		634.0K AUD
Employee benefits	390.0K AUD		365.0K AUD
Contingent consideration	0 AUD		3.3M AUD
Total current liabilities	14.1M AUD		25.8M AUD
Deferred tax	272.0K AUD		2.0M AUD
Employee benefits	37.0K AUD		35.0K AUD
Contingent consideration	0 AUD		3.8M AUD
Total non-current liabilities	309.0K AUD		5.8M AUD
Total liabilities	14.4M AUD		31.6M AUD
Contributed equity	123.0M AUD		101.6M AUD	97.5M AUD
Other contributed equity	380.0K AUD		0 AUD
Reserves	3.1M AUD		3.5M AUD	3.7M AUD
Accumulated losses	-134.8M AUD		-115.1M AUD
Total deficit	-8.3M AUD		-10.0M AUD
Total liabilities and shareholders' deficit	6.1M AUD		21.6M AUD

Period ending	2025-06-30	2024-12-31	2024-06-30	2023-06-30	2022-06-30
Cash and cash equivalents	4.3M AUD		1.7M AUD	5.2M AUD	7.4M AUD
Trade and other receivables	98.0K AUD		3.9M AUD
Other current assets	491.0K AUD		591.0K AUD
Total current assets	4.9M AUD		6.1M AUD
Other receivables	40.0K AUD		40.0K AUD
Intangibles	1.1M AUD	0 AUD	15.4M AUD	17.3M AUD
Total non-current assets	1.1M AUD		15.4M AUD
Total assets	6.1M AUD		21.6M AUD
Trade and other payables	10.1M AUD		15.1M AUD
Other financial liabilities	3.1M AUD		6.5M AUD	8.6M AUD
Borrowings	396.0K AUD		634.0K AUD
Employee benefits	390.0K AUD		365.0K AUD
Contingent consideration	0 AUD		3.3M AUD
Total current liabilities	14.1M AUD		25.8M AUD
Deferred tax	272.0K AUD		2.0M AUD
Employee benefits	37.0K AUD		35.0K AUD
Contingent consideration	0 AUD		3.8M AUD
Total non-current liabilities	309.0K AUD		5.8M AUD
Total liabilities	14.4M AUD		31.6M AUD
Contributed equity	123.0M AUD		101.6M AUD	97.5M AUD
Other contributed equity	380.0K AUD		0 AUD
Reserves	3.1M AUD		3.5M AUD	3.7M AUD
Accumulated losses	-134.8M AUD		-115.1M AUD
Total deficit	-8.3M AUD		-10.0M AUD
Total liabilities and shareholders' deficit	6.1M AUD		21.6M AUD

Cash from operations⁶⁷⁸⁹¹⁰²-13.3M AUD in 2025+53% since 2018

Every line of the cash flow as filed: the last 3 fiscal years, latest first.²

Period ending	2025-06-30	2024-06-30	2023-06-30
Loss after income tax expense for the year	-20.7M AUD	-26.8M AUD	-20.5M AUD
Amortisation	934.0K AUD	1.9M AUD	1.9M AUD
Issuance of liability classified warrants for services	1.5M AUD	6.0M AUD	0 AUD
Share-based payments	653.0K AUD	533.0K AUD	1.2M AUD
Foreign currency loss / (gain)	310.0K AUD	-20.0K AUD	46.0K AUD
Loss/(gain) on remeasurement of contingent consideration	-7.6M AUD	134.0K AUD	-2.1M AUD
Interest on unwinding of contingent consideration	232.0K AUD	0 AUD	0 AUD
Gain on remeasurement of promissory note	0 AUD	-25.0K AUD	0 AUD
Loss / (gain) on remeasurement of financial liabilities	982.0K AUD	-1.3M AUD	0 AUD
Impairment of intangible assets	13.4M AUD	0 AUD	0 AUD
Cash flows from used in operations before changes in working capital	-10.3M AUD	-19.6M AUD	-19.5M AUD
Trade and other receivables	3.8M AUD	5.0K AUD	3.5M AUD
Other assets	100.0K AUD	1.0M AUD	365.0K AUD
Trade and other payables	-5.0M AUD	10.7M AUD	569.0K AUD
Other provisions	27.0K AUD	-349.0K AUD	264.0K AUD
Deferred tax liability	-1.7M AUD	-271.0K AUD	-271.0K AUD
Borrowings	-238.0K AUD	-1.2M AUD	-45.0K AUD
Net cash used in operating activities	-13.3M AUD	-9.6M AUD	-15.2M AUD
Proceeds from issuance of shares, net of transaction costs	11.8M AUD	2.9M AUD	13.0M AUD
Proceeds from issuance of equity and pre-funded warrants	3.0M AUD	2.7M AUD	0 AUD
Proceeds from exercise of ordinary warrants	1.2M AUD	0 AUD	0 AUD
Proceeds from promissory note	0 AUD	776.0K AUD	0 AUD
Repayment of promissory note	0 AUD	-371.0K AUD	0 AUD
Net cash provided by financing activities	16.0M AUD	6.0M AUD	13.0M AUD
Net (decrease)/increase in cash and cash equivalents	2.7M AUD	-3.6M AUD	-2.2M AUD
Effects of exchange rate changes on cash	-16.0K AUD	12.0K AUD	64.0K AUD
Conversion of convertible promissory note	0 AUD	380.0K AUD	0 AUD
Unissued equity	380.0K AUD	0 AUD	0 AUD
Exercise of pre-funded warrants	8.8M AUD	864.0K AUD	0 AUD

Compare KAZIA THERAPEUTICS LTD with another company

Leadership

Who has led KAZIA THERAPEUTICS LTD, and when. Pick a name to see everywhere that person has worked.

Chief executive

John E. Friend Ii.2026–now

Chief financial officer

James E. Levine2026–now

2010201520202025

Chief executive officerJohn E. Friend Ii. Mar 18, 2026 to now¹¹
Chief financial officerJames E. Levine Jun 15, 2026 to now¹²

Board members and other officers (8)

VP, Finance and ControllerJeffrey Bonacorda Mar 18, 2026 to now¹³
Program DirectorJeremy Simpson Mar 18, 2026 to now¹⁴
Director, CMCDavid Cain Apr 1, 2026 to now¹⁵
Chief Scientific OfficerSudha Rao May 19, 2026 to now¹⁶
Board memberRobert F. Apple Mar 18, 2026 to now¹⁷
Board memberSteven R. S. Coffey Mar 18, 2026 to now¹⁸
Board memberEbru Davidson Jun 3, 2026 to now¹⁹
Board memberJosiah T. Austin Jan 5, 2007 to Feb 27, 2013²⁰

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerElissa Hansen named Jan 17, 2025 to Dec 18, 2025²¹
Executive OfficerKaren Krumeich named Dec 15, 2023²²
DirectorBryce Carmine named Dec 15, 2023 to Dec 18, 2025²¹

Former names

NOVOGEN LTDMar 6, 2002 to Nov 17, 2017³

Timeline

Mar 18, 2026New chief executive John E. Friend Ii. becomes CEO¹¹

Filings

370 filings to the SEC since October 2021: 5 annual reports, 18 insider forms, 24 large holders, 4 private raises, 319 other. The latest 20:

Oct 2, 2026SCHEDULE 13G/A EDGAR
Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 18, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Sep 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR

The 370 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Dauntless Investment Group, LLCSCHEDULE 13G/A, 5 filings Jun 13, 2025 to Oct 2, 2026²³
Jorey ChernettSCHEDULE 13G/A, 5 filings Jun 12, 2025 to Aug 19, 2026²⁴
Ikarian Capital, LLCSCHEDULE 13G/A, 2 filings Feb 17, 2026 to Aug 14, 2026²⁵
Lynwood Capital Management Inc.SCHEDULE 13G/A, 2 filings Jan 23, 2026 to Aug 14, 2026²⁶
Alumni Capital LPSCHEDULE 13G/A, 6 filings Jul 2, 2024 to Mar 30, 2026²⁷
ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 2024²⁸
PLATINUM INVESTMENT MANAGEMENT LTDSC 13G, 2 filings Feb 12, 2024 to Nov 6, 2024²⁹

Money raised

Private offerings the company reported to the SEC on Form D.

Dec 3, 2025Raised $55.3 million in a private offering of equity Form D: 65 investors so far Form D
Aug 4, 2025Raised $2.1 million in a private offering of equity Form D: 4 investors so far Form D
Jan 10, 2025Raised $2.1 million in a private offering of securities Form D: 1 investor so far Form D
Dec 5, 2023Raised $2 million in a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Boxer Capital Management, LLC	560,000	$7.9M	0.6%	New
Flputnam Investment Management Co	414,958	$5.8M	0.1%	+272,489
Bleichroeder LP	400,000	$5.6M	1.0%	No change
Ikarian Capital, LLC	396,201	$5.6M	0.9%	New
Dauntless Investment Group, LLC	354,208	$5.0M	8.6%	+274,376
Stonepine Capital Management, LLC	345,179	$4.9M	3.7%	No change
Point72 Asset Management, L.P.	200,300	$2.3M	0.0%	+300
Ensign Peak Advisors, Inc	110,778	$1.6M	0.0%	New
Millennium Management LLC	101,376	$1.4M	0.0%	New
UBS Group AG	81,090	$1.1M	0.0%	+67,156
J. Goldman & Co LP	68,491	$964.4K	0.0%	New
ADAR1 Capital Management, LLC	61,550	$866.6K	0.0%	New
Jane Street Group, LLC	57,140	$804.5K	0.0%	New
Barclays PLC	56,999	$802.5K	0.0%	+33,000
Susquehanna International Group, Llp	50,616	$712.7K	0.0%	New
Cooperman Leon G	50,000	$704.0K	0.0%	New
Westside Investment Management, Inc.	47,585	$670.0K	0.1%	−2,840
Morgan Stanley	46,606	$656.2K	0.0%	+45,606
Marshall Wace, Llp	44,231	$622.8K	0.0%	New
XTX Topco Ltd	31,186	$439.1K	0.0%	New
Bnp Paribas Financial Markets	30,090	$423.7K	0.0%	+29,009
Citadel Advisors LLC	28,509	$401.4K	0.0%	New
Raymond James Financial Inc	22,599	$318.2K	0.0%	+6,850
Sequoia Financial Advisors, LLC	20,003	$281.6K	0.0%	−39,997
Engineers Gate Manager LP	14,975	$210.8K	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKAZIA THERAPEUTICS LTD filings on SEC EDGAR
2
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2025
3
SEC EDGARKAZIA THERAPEUTICS LTD filings on SEC EDGAR
4
SEC EDGARKAZIA THERAPEUTICS LTD annual report, Item 1 (Business)
5
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2018
6
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2018
7
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2019
8
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2020
9
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2021
10
SEC EDGARKAZIA THERAPEUTICS LTD 10-K for fiscal 2022
11
SEC EDGARJohn E. Friend Ii., Chief executive officer
12
SEC EDGARJames E. Levine, Chief financial officer
13
SEC EDGARJeffrey Bonacorda, VP, Finance and Controller
14
SEC EDGARJeremy Simpson, Program Director
15
SEC EDGARDavid Cain, Director, CMC
16
SEC EDGARSudha Rao, Chief Scientific Officer
17
SEC EDGARRobert F. Apple, Board member
18
SEC EDGARSteven R. S. Coffey, Board member
19
SEC EDGAREbru Davidson, Board member
20
SEC EDGARJosiah T. Austin, Board member
21
SEC EDGARKAZIA THERAPEUTICS LTD Form D naming Elissa Hansen
22
SEC EDGARKAZIA THERAPEUTICS LTD Form D naming Karen Krumeich
23
SEC EDGARDauntless Investment Group, LLC SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD
24
SEC EDGARJorey Chernett SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD
25
SEC EDGARIkarian Capital, LLC SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD
26
SEC EDGARLynwood Capital Management Inc. SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD
27
SEC EDGARAlumni Capital LP SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD
28
SEC EDGARARMISTICE CAPITAL, LLC SC 13G/A on KAZIA THERAPEUTICS LTD
29
SEC EDGARPLATINUM INVESTMENT MANAGEMENT LTD SC 13G on KAZIA THERAPEUTICS LTD